UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/578,412	12/26/2006	Hilmar Bischoff	BHC 031059 PCT-US	1665
Barbara A. Shimei Director, Patents & Licensing Bayer HealthCare LLC - Pharmaceuticals 555 White Plains Road, Third Floor Tarrytown, NY 10591			EXAMINER	
			GEMBEH, SHIRLEY V	
			ART UNIT	PAPER NUMBER
			1628	
			MAIL DATE	DELIVERY MODE
			05/26/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	lication No. Applicant(s)	
	10/578,412	BISCHOFF ET AL.	
Office Action Summary	Examiner	Art Unit	
	SHIRLEY V. GEMBEH	1628	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	l. ely filed the mailing date of this communication. (35 U.S.C. § 133).	
Status			
 1) ☐ Responsive to communication(s) filed on 1/13/ 2a) ☐ This action is FINAL. 2b) ☐ This 3) ☐ Since this application is in condition for allowant closed in accordance with the practice under E 	action is non-final. nce except for formal matters, pro		
Disposition of Claims			
4) ☐ Claim(s) 1-3 and 6-26 is/are pending in the approach 4a) Of the above claim(s) 12-22 is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-3,6-11 and 23-26 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-3 and 6-26 are subject to restriction	n from consideration.		
Application Papers			
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the off Replacement drawing sheet(s) including the correction of the off the oath or declaration is objected to by the Example 11).	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of 	s have been received. s have been received in Applicati ity documents have been receive I (PCT Rule 17.2(a)).	on No ed in this National Stage	
Attachment(s) 1) \(\overline{\text{N}} \) Notice of References Cited (PTO-892)	4) ☐ Interview Summary	(PTO-413)	
2) Notice of Treferences Gled (170-692) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite	